Home page > Press Releases

Edit email address
Invalid email
Email Sent
 
Chiesi receives positive ESG rating from independent rating agency Cerved
Chiesi Group has received an ESG rating A with an overall ESG score of 73.7 out of 100 Cerved Rating Agency: “Chiesi is among the best performing companies in the Healthcare Products...
1/28
ARCHIVE PRESS RELEASE
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
New organisational order for the Chiesi Foundation
Chiesi Group receives European Marketing Authorisation for Trimbow® (beclometasone/formoterol/glycopyrronium) NEXThaler, an extrafine formulation fixed triple combination therapy for the treatment of moderate to severe COPD
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group: performance is up in 2020
CHIESI BRASIL IS CERTIFIED TOP EMPLOYER FOR THE 5th CONSECUTIVE YEAR
Chiesi holds the first Hackathon in partnership with POLI-USP
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi Group e Apotex Inc. finalizam acordo para aquisição do Ferriprox® (deferiprona)
Chiesi Group Announces Establishment of New Global Rare Diseases Division
CHIESI BRASIL É CERTIFICADA GREAT PLACE TO WORK
Chiesi Group confirmed Top Employer 2020 in Italy and Europe
Anvisa aprova a primeira combinação tripla fixa extrafina para tratamento da DPOC no Brasil.
We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035
Chiesi Group confirms positive trend to date for 2019
Grupo Chiesi é a maior empresa farmacêutica no mundo a ser premiada com a certificação B Corporation
Chiesi´s people management practices are recognized by global entity
Chiesi is the first pharmaceutical company recognized as “Pró-Ética
Innovative threatment for COPD has its first data published
For the second time, Chiesi’s extra fine fixed ICS/LABA/LAMA triple combination therapy wins a place in the pages of 'The Lancet', with the publication of the TRINITY study conducted by Chiesi.
Pharmaceutical company marks its 40th anniversary in Brazil with factory expansion
Chiesi joins the